Loading…

Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity

Intravitreal antiangiogenic therapy is currently the most invasive ophthalmic procedure performed worldwide. This study aimed to describe the clinical and epidemiological profile of patients undergoing intravitreal antiangiogenic therapy in a tertiary referral hospital in Brazil. This cross-sectiona...

Full description

Saved in:
Bibliographic Details
Published in:Arquivos brasileiros de oftalmologia 2023, Vol.87 (5), p.e20220119
Main Authors: Rabelo, Isadora Andrade, Soares, Marina Crespo, Torigoe, Andrea Mara Simões
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 5
container_start_page e20220119
container_title Arquivos brasileiros de oftalmologia
container_volume 87
creator Rabelo, Isadora Andrade
Soares, Marina Crespo
Torigoe, Andrea Mara Simões
description Intravitreal antiangiogenic therapy is currently the most invasive ophthalmic procedure performed worldwide. This study aimed to describe the clinical and epidemiological profile of patients undergoing intravitreal antiangiogenic therapy in a tertiary referral hospital in Brazil. This cross-sectional, retrospective, and observational study analyzed medical records of patients who received intravitreal injections of antiangiogenic agents for the treatment of retinal diseases at the ophthalmology outpatient clinic in the Hospital das Clínicas at Unicamp between January and December 2020. The study included 429 patients and 514 eyes. The study population was predominantly male (51.28%), white (80.89%), between 50 and 80 years old (mean age, 60.92 years), had complete or incomplete first-grade education (56.88%), and did not belong to the Regional Health Department of which Campinas is a part (78.55%). Bevacizumab was the most commonly used intravitreal injectable medicine (79.38%), pro re nata was the most commonly used treatment regimen (90.27%), and macular edema was the most prevalent pathology indicative of treatment (60.12%), with diabetes etiology accounting for 48.25%. The average number of injections per patient was 3.83, with the macular neovascularization group and the pro re nata group having the highest and lowest with five and three injections, respectively. Treatment adherence was associated with the patient's pathology, and the macular edema (52.24%) and macular neovascularization (49.48%) groups had the lowest adherence rates. This study evaluated the epidemiological and clinical profile of patients undergoing antiangiogenic therapy in a high-complexity public hospital, which is fundamental for a better understanding of the demand for ophthalmic reference service in Brazil, and the analysis of functional results and user adherence profile promotes optimization of indications and leverages the benefits of intravitreal therapy.
doi_str_mv 10.5935/0004-2749.2022-0119
format article
fullrecord <record><control><sourceid>proquest_sciel</sourceid><recordid>TN_cdi_scielo_journals_S0004_27492023005006203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S0004_27492023005006203</scielo_id><sourcerecordid>3107157491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-9cf4d5bd2cfda7d11529b6bc35216e8a987a05a4eb9f9caaadbbbfd84b1a04903</originalsourceid><addsrcrecordid>eNpVUU1vEzEQtRAVDYVfgIR85LLBH-vd-ISg4kuqRKWWszX2ziaunHWwnUD49XiVEsFppJn35s28R8grzpZKS_WWMdY2om_1UjAhGsa5fkIWvOtXjdBCPSWLM-KSPM_5gTHRaq2ekUuphV71ol-Q422Kow9I40h3UDxOJdOSEAoO9KcvG-qnkuDg516gMBUP09rHNU7e5TqkQD8k-O1D7dPd3gbvaMZ08A5P_I1fb2jAA4ZZw8XtLuAvX44vyMUIIePLx3pFvn_6eH_9pbn59vnr9fubxkmtSqPd2A7KDsKNA_QD50po21knleAdrqD-AUxBi1aP2gHAYK0dh1VrObBWM3lFlqe92XkM0TzEfZqqoLmb7TGzPdU_yZhirBNMVsK7E6F-s8XB4WxAMLvkt5COJoI3_08mvzHreDCcd0K2bVc3vHnckOKPPeZitj47DAEmjPtsJGc9V1WYV6g8QV2KOScczzqcmTlmc77SzDGbOebKev3viWfO31zlH1M2pSg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3107157491</pqid></control><display><type>article</type><title>Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity</title><source>SciELO Brazil</source><creator>Rabelo, Isadora Andrade ; Soares, Marina Crespo ; Torigoe, Andrea Mara Simões</creator><creatorcontrib>Rabelo, Isadora Andrade ; Soares, Marina Crespo ; Torigoe, Andrea Mara Simões</creatorcontrib><description>Intravitreal antiangiogenic therapy is currently the most invasive ophthalmic procedure performed worldwide. This study aimed to describe the clinical and epidemiological profile of patients undergoing intravitreal antiangiogenic therapy in a tertiary referral hospital in Brazil. This cross-sectional, retrospective, and observational study analyzed medical records of patients who received intravitreal injections of antiangiogenic agents for the treatment of retinal diseases at the ophthalmology outpatient clinic in the Hospital das Clínicas at Unicamp between January and December 2020. The study included 429 patients and 514 eyes. The study population was predominantly male (51.28%), white (80.89%), between 50 and 80 years old (mean age, 60.92 years), had complete or incomplete first-grade education (56.88%), and did not belong to the Regional Health Department of which Campinas is a part (78.55%). Bevacizumab was the most commonly used intravitreal injectable medicine (79.38%), pro re nata was the most commonly used treatment regimen (90.27%), and macular edema was the most prevalent pathology indicative of treatment (60.12%), with diabetes etiology accounting for 48.25%. The average number of injections per patient was 3.83, with the macular neovascularization group and the pro re nata group having the highest and lowest with five and three injections, respectively. Treatment adherence was associated with the patient's pathology, and the macular edema (52.24%) and macular neovascularization (49.48%) groups had the lowest adherence rates. This study evaluated the epidemiological and clinical profile of patients undergoing antiangiogenic therapy in a high-complexity public hospital, which is fundamental for a better understanding of the demand for ophthalmic reference service in Brazil, and the analysis of functional results and user adherence profile promotes optimization of indications and leverages the benefits of intravitreal therapy.</description><identifier>ISSN: 0004-2749</identifier><identifier>ISSN: 1678-2925</identifier><identifier>EISSN: 1678-2925</identifier><identifier>DOI: 10.5935/0004-2749.2022-0119</identifier><identifier>PMID: 39298727</identifier><language>eng</language><publisher>Brazil: Conselho Brasileiro de Oftalmologia</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - administration &amp; dosage ; Angiogenesis Inhibitors - therapeutic use ; Bevacizumab - administration &amp; dosage ; Bevacizumab - therapeutic use ; Brazil ; Cross-Sectional Studies ; Female ; Humans ; Intravitreal Injections ; Macular Edema - drug therapy ; Male ; Middle Aged ; OPHTHALMOLOGY ; Original ; Retinal Diseases - drug therapy ; Retrospective Studies</subject><ispartof>Arquivos brasileiros de oftalmologia, 2023, Vol.87 (5), p.e20220119</ispartof><rights>This work is licensed under a Creative Commons Attribution 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-1621-7661</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,24150,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39298727$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rabelo, Isadora Andrade</creatorcontrib><creatorcontrib>Soares, Marina Crespo</creatorcontrib><creatorcontrib>Torigoe, Andrea Mara Simões</creatorcontrib><title>Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity</title><title>Arquivos brasileiros de oftalmologia</title><addtitle>Arq Bras Oftalmol</addtitle><description>Intravitreal antiangiogenic therapy is currently the most invasive ophthalmic procedure performed worldwide. This study aimed to describe the clinical and epidemiological profile of patients undergoing intravitreal antiangiogenic therapy in a tertiary referral hospital in Brazil. This cross-sectional, retrospective, and observational study analyzed medical records of patients who received intravitreal injections of antiangiogenic agents for the treatment of retinal diseases at the ophthalmology outpatient clinic in the Hospital das Clínicas at Unicamp between January and December 2020. The study included 429 patients and 514 eyes. The study population was predominantly male (51.28%), white (80.89%), between 50 and 80 years old (mean age, 60.92 years), had complete or incomplete first-grade education (56.88%), and did not belong to the Regional Health Department of which Campinas is a part (78.55%). Bevacizumab was the most commonly used intravitreal injectable medicine (79.38%), pro re nata was the most commonly used treatment regimen (90.27%), and macular edema was the most prevalent pathology indicative of treatment (60.12%), with diabetes etiology accounting for 48.25%. The average number of injections per patient was 3.83, with the macular neovascularization group and the pro re nata group having the highest and lowest with five and three injections, respectively. Treatment adherence was associated with the patient's pathology, and the macular edema (52.24%) and macular neovascularization (49.48%) groups had the lowest adherence rates. This study evaluated the epidemiological and clinical profile of patients undergoing antiangiogenic therapy in a high-complexity public hospital, which is fundamental for a better understanding of the demand for ophthalmic reference service in Brazil, and the analysis of functional results and user adherence profile promotes optimization of indications and leverages the benefits of intravitreal therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - administration &amp; dosage</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Bevacizumab - administration &amp; dosage</subject><subject>Bevacizumab - therapeutic use</subject><subject>Brazil</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Macular Edema - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>OPHTHALMOLOGY</subject><subject>Original</subject><subject>Retinal Diseases - drug therapy</subject><subject>Retrospective Studies</subject><issn>0004-2749</issn><issn>1678-2925</issn><issn>1678-2925</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVUU1vEzEQtRAVDYVfgIR85LLBH-vd-ISg4kuqRKWWszX2ziaunHWwnUD49XiVEsFppJn35s28R8grzpZKS_WWMdY2om_1UjAhGsa5fkIWvOtXjdBCPSWLM-KSPM_5gTHRaq2ekUuphV71ol-Q422Kow9I40h3UDxOJdOSEAoO9KcvG-qnkuDg516gMBUP09rHNU7e5TqkQD8k-O1D7dPd3gbvaMZ08A5P_I1fb2jAA4ZZw8XtLuAvX44vyMUIIePLx3pFvn_6eH_9pbn59vnr9fubxkmtSqPd2A7KDsKNA_QD50po21knleAdrqD-AUxBi1aP2gHAYK0dh1VrObBWM3lFlqe92XkM0TzEfZqqoLmb7TGzPdU_yZhirBNMVsK7E6F-s8XB4WxAMLvkt5COJoI3_08mvzHreDCcd0K2bVc3vHnckOKPPeZitj47DAEmjPtsJGc9V1WYV6g8QV2KOScczzqcmTlmc77SzDGbOebKev3viWfO31zlH1M2pSg</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Rabelo, Isadora Andrade</creator><creator>Soares, Marina Crespo</creator><creator>Torigoe, Andrea Mara Simões</creator><general>Conselho Brasileiro de Oftalmologia</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>GPN</scope><orcidid>https://orcid.org/0000-0003-1621-7661</orcidid></search><sort><creationdate>202301</creationdate><title>Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity</title><author>Rabelo, Isadora Andrade ; Soares, Marina Crespo ; Torigoe, Andrea Mara Simões</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-9cf4d5bd2cfda7d11529b6bc35216e8a987a05a4eb9f9caaadbbbfd84b1a04903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - administration &amp; dosage</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Bevacizumab - administration &amp; dosage</topic><topic>Bevacizumab - therapeutic use</topic><topic>Brazil</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Macular Edema - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>OPHTHALMOLOGY</topic><topic>Original</topic><topic>Retinal Diseases - drug therapy</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rabelo, Isadora Andrade</creatorcontrib><creatorcontrib>Soares, Marina Crespo</creatorcontrib><creatorcontrib>Torigoe, Andrea Mara Simões</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SciELO</collection><jtitle>Arquivos brasileiros de oftalmologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rabelo, Isadora Andrade</au><au>Soares, Marina Crespo</au><au>Torigoe, Andrea Mara Simões</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity</atitle><jtitle>Arquivos brasileiros de oftalmologia</jtitle><addtitle>Arq Bras Oftalmol</addtitle><date>2023-01</date><risdate>2023</risdate><volume>87</volume><issue>5</issue><spage>e20220119</spage><pages>e20220119-</pages><issn>0004-2749</issn><issn>1678-2925</issn><eissn>1678-2925</eissn><abstract>Intravitreal antiangiogenic therapy is currently the most invasive ophthalmic procedure performed worldwide. This study aimed to describe the clinical and epidemiological profile of patients undergoing intravitreal antiangiogenic therapy in a tertiary referral hospital in Brazil. This cross-sectional, retrospective, and observational study analyzed medical records of patients who received intravitreal injections of antiangiogenic agents for the treatment of retinal diseases at the ophthalmology outpatient clinic in the Hospital das Clínicas at Unicamp between January and December 2020. The study included 429 patients and 514 eyes. The study population was predominantly male (51.28%), white (80.89%), between 50 and 80 years old (mean age, 60.92 years), had complete or incomplete first-grade education (56.88%), and did not belong to the Regional Health Department of which Campinas is a part (78.55%). Bevacizumab was the most commonly used intravitreal injectable medicine (79.38%), pro re nata was the most commonly used treatment regimen (90.27%), and macular edema was the most prevalent pathology indicative of treatment (60.12%), with diabetes etiology accounting for 48.25%. The average number of injections per patient was 3.83, with the macular neovascularization group and the pro re nata group having the highest and lowest with five and three injections, respectively. Treatment adherence was associated with the patient's pathology, and the macular edema (52.24%) and macular neovascularization (49.48%) groups had the lowest adherence rates. This study evaluated the epidemiological and clinical profile of patients undergoing antiangiogenic therapy in a high-complexity public hospital, which is fundamental for a better understanding of the demand for ophthalmic reference service in Brazil, and the analysis of functional results and user adherence profile promotes optimization of indications and leverages the benefits of intravitreal therapy.</abstract><cop>Brazil</cop><pub>Conselho Brasileiro de Oftalmologia</pub><pmid>39298727</pmid><doi>10.5935/0004-2749.2022-0119</doi><orcidid>https://orcid.org/0000-0003-1621-7661</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0004-2749
ispartof Arquivos brasileiros de oftalmologia, 2023, Vol.87 (5), p.e20220119
issn 0004-2749
1678-2925
1678-2925
language eng
recordid cdi_scielo_journals_S0004_27492023005006203
source SciELO Brazil
subjects Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - therapeutic use
Bevacizumab - administration & dosage
Bevacizumab - therapeutic use
Brazil
Cross-Sectional Studies
Female
Humans
Intravitreal Injections
Macular Edema - drug therapy
Male
Middle Aged
OPHTHALMOLOGY
Original
Retinal Diseases - drug therapy
Retrospective Studies
title Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A44%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sciel&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Profile%20of%20patients%20treated%20with%20intravitreal%20antiangiogenics%20in%20a%20Brazilian%20public%20service%20with%20high%20level%20of%20complexity&rft.jtitle=Arquivos%20brasileiros%20de%20oftalmologia&rft.au=Rabelo,%20Isadora%20Andrade&rft.date=2023-01&rft.volume=87&rft.issue=5&rft.spage=e20220119&rft.pages=e20220119-&rft.issn=0004-2749&rft.eissn=1678-2925&rft_id=info:doi/10.5935/0004-2749.2022-0119&rft_dat=%3Cproquest_sciel%3E3107157491%3C/proquest_sciel%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c395t-9cf4d5bd2cfda7d11529b6bc35216e8a987a05a4eb9f9caaadbbbfd84b1a04903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3107157491&rft_id=info:pmid/39298727&rft_scielo_id=S0004_27492023005006203&rfr_iscdi=true